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Background: Circumferential endoscopic submucosal dissection (CESD) of the esophagus would allow for both the
eradication of Barrett’s esophagus and its related complications, such as advanced neoplasia. However, such
procedures generally induce inflammatory repair resulting in a fibrotic stricture. N-acetylcysteine (NAC) is an
antioxidant that has shown some efficacy against pulmonary and hepatic fibrosis. The aim of our study was to
evaluate the benefit of NAC in the prevention of esophageal cicatricial stricture after CESD in a swine model.
Animals and methods: Two groups of six pigs each were subjected to general anesthesia and CESD: after
randomization, a first group received an oral NAC treatment regimen of 100 mg/kg/day, initiated one week before
the procedure, whereas a second group was followed without any prophylactic treatment. Follow-up endoscopies
took place seven, fourteen, twenty-one, and twenty-eight days after CESD. Necropsy, histological assessment of
esophageal inflammation, and fibrosis were performed on day 28.
Results: The median esophageal lumen diameter on day 21 (main judgment criterion) was 4 mm (range 2 to 5) in
group 1 and 3 mm (range 1 to 7) in group 2 (P= 0.95). No significant difference was observed between the two
groups regarding clinical evaluation (time before onset of clinically significant esophageal obstruction), number of
dilations, esophageal inflammation and fibrosis, or oxidative stress damage on immunohistochemistry.
Conclusions: Despite its antioxidant effect, systemic administration of NAC did not show significant benefit on
esophageal fibrosis in our animal model of esophageal wound healing within the experimental conditions of this
study. Since the administered doses were relatively high, it seems unlikely that NAC might be a valuable option for
the prevention of post-endoscopic esophageal stricture.
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Early esophageal adenocarcinomaBackground
Endoscopic resection of Barrett’s esophagus with a high-
grade dysplasia or early esophageal cancer has become an
acceptable therapeutic option [1-3], alongside surgical eso-
phagectomy. Endoscopic mucosal resection is easily feas-
ible but leads to a piecemeal, non-carcinologic resection* Correspondence: frederic.prat@cch.aphp.fr
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reproduction in any medium, provided the orof neoplastic tissue, whereas endoscopic submucosal dis-
section (ESD) is more carcinologically efficient, although
more technically challenging. Nonetheless, both techni-
ques result in cicatricial fibroinflammatory esophageal
strictures when 75% or more of the mucosal circumfer-
ence is removed [4,5]. These strictures may require nu-
merous endoscopic dilations, jeopardizing the patients’
quality of life and risking esophageal perforation. This is
believed to result from local inflammatory reactions, as
well as subsequent cicatricial fibrosis [4,6-8]. Furthermore,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Esophageal stricture following circumferential
endoscopic submucosal dissection. Endoscopic view (A) and
gross morphology (B).
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esophagus has been linked to the production of reactive
oxygen species [9].
We developed an endoscopic submucosal dissection
technique in a swine model, allowing for quick and safe
en bloc circumferential resection of the esophageal mu-
cosa [10]. A similar technique has been described since
[11]. This method consists of a classical endoscopic sub-
mucosal dissection and blunt mechanical dissection
using an endoscopic mucosectomy cap. It allows for en
bloc resection of mucosal and submucosal cylinders up
to 15 centimeters, without taking longer or causing
more immediate complications than endoscopic mucosal
resection alone. However, tight oesophageal strictures al-
ways develop in this model between the eighth and the
fifteenth postoperative day.
N-acetylcysteine (NAC) is an antioxidant molecule
with antifibrotic properties [12,13], mainly related to
the inhibition of transforming growth factor-beta
(TGF-β) signaling [14]. It has an anti-inflammatory ef-
fect caused by downregulating TNF-α, IL-6, and IL-8
synthesis [15]. Furthermore, it is a cheap, readily avail-
able, and a safe molecule. NAC has shown efficiency
in pulmonary fibrosis [16] and is of possible interest
in cirrhotic [17], nonalcoholic steatohepatitis [18] liver
fibrosis, and improved wound healing of tympanic
membranes [19]. In the esophagus, anastomotic wound
healing improved with NAC administration [20].
Therefore, we conducted a controlled trial to assess
the interest of NAC in the prevention of esophageal
strictures, following circumferential ESD in our swine
model.
Results
The median esophageal diameter on the 21st postopera-
tive day was 4 mm (range 2 to 5) in group 1 (treated
with NAC) and 3 mm (range 1 to 7) in group 2 (control)
(P= 0.95) (Figures 1 and 2).
In group 1, none of the six animals exhibited abnormal
behavior, but five out of six (83%) were unable to ingest
a regular diet after fourteen days because of regurgita-
tions. In group 2, one pig out of five (20%) was found to
be asthenic, and four out of five (80%) were unable to
eat because of their esophageal stricture. Overall number
of dilation was 13 (2.2 per pig) in group 1 and 12 (2 per
pig) in group 2 on day 21 (P=NS).
At necropsy, mediastinal periesophageal lymph nodes
with evidence for mediastinal inflammation, but no
other feature of mediastinitis, were diagnosed in one
pig in each group, probably as a result of repeated dila-
tions. In Group 2, two animals experienced an esopha-
geal perforation related to the endoscopic procedure:
one was successfully treated with endoscopic clips and
antibiotherapy and the other required euthanasia. Oneof the pigs from Group 2 died of mediastinitis following
esophageal dilation on day 22. The number of esopha-
geal dilations and complications recorded during
follow-up for each animal are presented in Table 1.
Histology revealed two different patterns that were
found indistinctively in both groups. In the first one
(Figure 3), the superficial layer remained ulcerated; we
observed a dense granulation tissue with a major inflam-
matory cell infiltrate and high cell density with predom-
inance of polynuclear leukocytes in the remaining
submucosa; we also observed myofibroblasts in the sub-
mucosal and muscular layers, surrounded by fibrosis
(Figure 3, A2 and B2). Conversely, we observed a neoe-
pithelium in the second pattern (Figure 4), characterized
by a single layer of immature epithelial cells. Fibrosis
(Figure 4, A2 and B2) was found underneath the neoe-
pithelium, around myofibroblasts and fibroblasts, filling
the submucosal layer and dissecting muscular fibers;
associated with moderate, lymphoplasmocytic inflamma-
tory cell infiltrate, and granulation tissue (Figure 4, A
and B). These two patterns can be hypothesized as cor-
responding to the early and late phases of the same in-
flammatory and fibrotic cicatricial process. Median
fibrosis thickness was 1740 μm (range 1030 to 2570) in
group 1 vs 1915 μm (range 1710 to 2860) in group 2,
Figure 2 Esophageal stricture following circumferential
endoscopic submucosal dissection, endoscopic view (A) and
microscopic view (B) (Masson’s trichrome, original magnified
x12.5) showing the corresponding histological feature.
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1000 μm (range 925 to 1100) in group 1 vs 843 μm
(range 868 to 2440) in group 2, P=NS. The granulation
tissue presented with features of acute inflammation in
30% of cases in group 1 vs 25% in group 2. Immunohis-
tochemistry staining with 8-hydroxy-2’ deoxyguanosine
(8-OH DG) antibody showed a more intense signal in
the esophageal wall of control animals as compared to
NAC-treated animals (Figure 5). This finding was con-
sistently observed on all slides. However, signal measure-
ments did not show a statistically significant difference
between the groups: median: 148 (range 122 to 169) in
group 1 vs 136 (range 90 to 168) in group 2, P= 0.54.
Discussion
This study is the first one to evaluate, on a swine model,
the systemic administration of an antioxidant molecule
in the prevention of esophageal strictures.
Nonetheless, this work did not demonstrate any clin-
ical, endoscopical, or histological benefit of NAC to pre-
vent oesophageal stenosis after circumferential ESD. A
first hypothesis is an insufficient oral intake of NAC in
regurgitating animals, despite repeated esophageal dila-
tions. However, if solid food intake is impaired byesophageal stricture, liquid intake is almost always pos-
sible. Moreover, food intake remained normal during the
first 10 days, the period during which NAC was
expected to exert its maximal beneficial effect, if any. An
intravenous route for NAC would have required daily in-
vasive treatment administration, and sedation of the ani-
mals, which did not seem acceptable; furthermore, oral
and intravenous administrations have been reported to
be equivalent [21]. Doses of NAC vary from 20 mg/kg to
400 mg/kg of body weight per day. Given that the bio-
availability of orally administrated NAC is low (<10%),
we decided to use high doses, closer to those used in
acetaminophen poisoning than in chronic fibrotic dis-
eases [22]. The pigs were put on a 60 mg/kg/day dose of
NAC as part of a preliminary experiment and results
showed improvement of the esophageal diameter at day
15 with no side effects. This propelled us to increase the
NAC dose to 100 mg/kg/day. The use of higher doses,
up to 400 mg/kg/day, has been reported, but is com-
monly associated with frequent side effects [23]. Such
anaphylactoïd reactions, including vomiting, could have
biased the evaluation of food intake, esophageal mucosa,
Figure 3 Histological analysis of the resected esophagus with
predominant inflammatory pattern. Absence of neoepithelium,
granulation tissue with an important inflammatory cell infiltrate of
the submucosal layer; submucosal fibrosis is highlighted by Masson’s
trichrome staining. (A1) Untreated swine, hematoxylin-eosin-safran
(HES), original magnified x12.5. (A2) Untreated swine, Masson’s
trichrome, original magnified x12.5. (B1) Treated by N-acetylcysteine
(NAC), HES, original magnified x25. (B2) Treated by NAC, Masson’s
trichrome, original magnified x25.
Figure 4 Histological analysis of the resected esophagus with
predominant fibrotic pattern. Presence of a neoepithelium, as a
single layer of immature epithelial cells, a thin granulation tissue
with moderate cell density, and important thickness of cicatricial
fibrosis infiltrating the remaining submucosal and the muscular
layer. (A1) Untreated swine, hematoxylin-eosin-safran (HES), original
magnified x25. (A2) Untreated swine, Masson’s trichrome, original
magnified x25. (B1) Treated by N-acetylcysteine (NAC), HES,
original magnified x25. (B2) Treated by NAC, Masson’s trichrome,
original magnified x25.
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not record such anaphylactoïd reactions in the animals
we treated. However, insufficient local concentration
could also explain these results and could warrant an-
other attempt of NAC administration, directly into
esophageal wounds.
The second issue is the timing of the clinical and
histological assessment. We chose the 21st postoperative
day as the day of endpoint assessment because it was
consistent with the timing of stricture development in
this model, generally observable between days 10 and 15
after ESD. Animals were kept in good condition after
day 15, using iterative endoscopic dilations. Of note is
the fact that these dilations might have played a role in
the delayed reepithelialisation observed in some animals.
It can be hypothesized that an earlier assessment of clin-
ical and histological endpoints might have shown a more
significantly different data, but the absence of any ob-
servable benefit at 21 days suggests such findings wouldnot have been highly relevant to further clinical use of
NAC.
A third hypothesis for NAC inefficiency is the severe
and systematic nature of oesophageal strictures in pigs
(possibly due to continuous acid aggression in condi-
tions of stress). This makes our swine model particularly
heuristic for the study of stricture development and pre-
vention: if a treatment provides positive clinical results
in this model, it should be all the more efficient in
humans, but one would expect that NAC should at least
exhibit some histological effect.
NAC has been found to have a direct antioxidant ef-
fect as well as to stimulate glutathione synthesis, a
major endogenous intracellular antioxidant. It also
plays a role in modulating the proinflammatory cyto-
kine response [24], notably by inhibiting TGF-β1 [12]
and abrogating the fibrogenic properties of pathological
fibroblasts [14]. Post-endoscopic esophageal strictures
are characterized by an intense local inflammatory
Figure 5 Immunohistochemical staining with 8-hydroxy-2’
deoxyguanosine antibody. Strong signal predominant in
perivascular region in control (A) and almost absent signal in treated
swine (B).
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and quickly makes way for cicatricial fibrosis. An
increased level of reactive oxygen species (ROS) has
been reported in esophageal ulcers, with the benefit of
an antioxidant molecule (vitamin E) administration on
esophageal wound healing [9]; along with these results,
many stricture-preventing drugs, either antioxidant
[25], antifibrotic [26-30], or anti-inflammatory [4,7,31],
have been tested on esophageal wounds. The only
treatment reported to be beneficial against esophageal
strictures in human studies is local corticosteroid in-
jection [4], although these results are contradictory,
with previous animal studies reporting severe compli-
cations related to triamcinolone injection [7]. These
data have led us to consider NAC for post-endoscopic
esophageal stricture prevention. Despite an antioxidant
effect suggested by the results of immunohistochemis-
try (although the difference between both signals on
quantitative measurements did not reach statistical
significance), NAC did not, in our work, prevent esopha-
geal stricture.
Considering our results, it seems that several mechan-
isms could be at stake in cicatricial esophageal fibrosis.
In particular, mucosal defect and resulting acid, andbacterial aggressions of the submucosa could play a role;
therefore, stricture prevention strategies focusing on
covering and protecting the injured esophagus should be
developed, even if recent studies, including ones done
on humans, either report insufficient efficacy [32], or
show an improvement of esophageal wound healing only
in partial mucosal defects [7,8,33-35], where strictures
are uncommon. However, the use of growth factors,
extracellular membranes, or bio-scaffolds or cellular
therapy, makes their translation into daily practice un-
likely for the present moment. This data confirm that
preventive treatment should prevail against curative ones
regarding post-endoscopic esophageal strictures.
Conclusions
Our study failed to prove that an antioxidant such as
NAC can improve the outcome of tissue repair in a
model of severe post-ESD esophageal stricture, when
used as a single agent. Its antioxidant activity did not
prevent fibroinflammatory cicatricial esophageal stric-
ture formation at the 21st postoperative day. Extensive
esophageal endoscopic submucosal dissection might be-
come an alternative choice to esophagectomy for
Barrett’s esophagus with high-grade dysplasia or early
adenocarcinoma; hence, further analysis of esophageal




The experimental protocol received approval from the sci-
entific committee of the Surgical School of Paris (Ecole de
Chirurgie de l’Assistance Publique des Hôpitaux de Paris,
7 rue du Fer à Moulin, 75005 Paris, France), and experi-
ments were performed according to the standard guide-
lines of the French Ministry of Agriculture that regulates
animal research in France.
Twelve 30 to 35 kg pigs, originating from the same
farm, were used in the study. The pigs were accommo-
dated at our facility 48 hours before the procedure took
place. Endoscopies were performed under general
anesthesia. All animals were prepared for anesthesia with
a 12-hour diet and were administered an intramuscular
injection of 10 mg/kg ketamine and 2 mg/kg azaperone,
30 minutes before induction. Following induction with
8 mg/kg intravenous 1% propofol and endotracheal in-
tubation, anesthesia was maintained through inhalation
of 1% to 2% isoflurane. All animals received an intraven-
ous infusion of 10 mg/kg/h crystalloid solution.
Endoscopic submucosal dissection procedure
Upper gastrointestinal endoscopies were performed using a
standard gastroscope (Fujinon EG450D; Fujinon, Sataima,
Japan), through an overtube. A senior endoscopist carried
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Circumferential submucosal endoscopic dissection of the
distal third of the esophagus was performed according to
the previously reported technique [10]. Briefly, two circum-
ferential incisions reaching the superficial submucosal layer
were made following a submucosal injection of indigo
carmine-stained saline; these two incisions defined a muco-
sal cylinder of 5 cm in the lower third of the esophagus,
5 cm above the gastroesophageal junction. The cylinder
was removed by blunt submucosal dissection, using a
mucosectomy cap (ST hood DH-19 GR; Fujinon, Sataima,
Japan), which allowed for cleaving of the mucosa and
superficial submucosa from the underlying submucosa by
gently scraping the esophageal wall in a back and forth mo-
tion, from the proximal to the distal incision. The resected
mucosal cylinder was then retrieved using the endoscope’s
suction channel.Study design
Twelve pigs were randomly allocated to a treatment and a
control group. The first group of six pigs was given
100 mg/kg/day of NAC (Mucomyst; Bristol-Myers Squibb,
Princeton, NJ, USA) in drinking water for seven days be-
fore the procedure. After circumferential endoscopic sub-
mucosal dissection (CESD), the pigs received NAC
treatment, at the same dose, until the 21st postoperative
day. A seven-day course of omeprazole 40 mg/day and
broad-spectrum antibiotics was also given: 10 mg/kg
extended-release benzathine benzylpenicillin G+penicillin
procaine (Duphapen; Pfizer, NewYork, NY, USA) for the
first four days; then 1 g/day amoxicillin (ClamoxylW,
GlaxoSmithKline, Brentford, UK) for three days. The con-
trol group (group 2) received proton-pump inhibitors and
broad-spectrum antibiotics at the same doses.
The animals were given a liquid diet following each
procedure, and were gradually introduced to a solid food
diet. The pigs were kept in the Surgical School of Paris
with daily examination and weekly veterinary follow-up
and endoscopic examination. An endoscopic balloon
dilation was performed if clinical symptoms suggested
that an esophageal stricture had occurred. Investigators
prospectively collected clinical data on a weekly basis,
such as global clinical status, which included general be-
havior, food intake, and occurrence of regurgitations or
vomiting. Investigators also recorded any endoscopic
findings, width of esophageal lumen (evaluated with a
biopsy forceps), and number of balloon dilations.
Twenty-eight days after the procedure, or earlier in
case of major complication (esophageal perforation,
death), animals were euthanized with 100 mg/kg intra-
venous injection of 7 mg pentobarbital (Dolethal;
Vétoquinol, Paris, France), and underwent a necropsy
with esophagectomy afterward.Histological analysis
Specimens were fixed in 10% buffered formalin, embed-
ded in paraffin, and processed into 5 μm-thick sections,
after gross morphological examination of the size, weight,
and thickness of the esophageal wall. The specimens were
then stained with hematoxylin-eosin-safran (HES), and
Masson’s trichrome. Histological slides were digitized
with the NDPI Nanozoomer (Hamamatsu Photonics,
Hamamatsu City, Japan), and submitted to quantitative
analysis of fibrosis, granulation tissue, and inflammatory
cell infiltrate by a senior pathologist expert in digestive
pathology. The following measurements were made on
each digitized image of trichrome-stained slides: maximal
thickness of fibrosis, from the muscularis propria to the
epithelium, and maximal thickness of the granulation tis-
sue, from the esophageal lumen to the submucosal fibro-
sis. Furthermore, the inflammatory cell infiltrate was
characterized as being acute (predominance of poly-
nuclear cells, high cell density) or chronic (predominance
of lymphocytes or plasmocytes, low cell density).
Immunohistochemistry on paraffin sections was per-
formed with monoclonal antibodies to 8-hydroxy-2’ deox-
yguanosine (8-OH DG) (ab26842; Abcam, Cambridge,
UK) and goat polyclonal secondary antibodies to mouse
IgG1 (ab 97240; Abcam, Cambridge, UK), in order to
assess the intensity of oxidative stress in the esophageal
wall. The intensity of the signal was analyzed using the
ImageJ software, the highest numbers corresponding to
the lowest signal.Statistical analysis
Statistical analysis was performed using GraphPad Prism
(GraphPad Software, La Jolla, CA, USA). Continuous
data is expressed as median values and range, and com-
pared with a nonparametric Mann–Whitney test. Cat-
egorical data is expressed in percentages and compared
with a Fisher’s exact test.End points
The primary end point was the diameter of the esopha-
gus measured via endoscopy on day 21 following the
operation.
The secondary end points were: global clinical evalu-
ation of the pigs on day 21, number of endoscopic dila-
tions required, thickness of the granulation tissue and
the fibrotic layer in the esophageal wall, and antioxidant
effect of NAC, as measured by 8-OH DG staining.Abbreviations
CESD: Circumferential endoscopic submucosal dissection; HES: Hematoxylin-
eosin-safran; IL: Interleukin; NAC: N-acetylcysteine; NS: Not significant;
ROS: Reactive oxygen species; 8-OH DG: 8-hydroxy-2’ deoxyguanosine;
TGF: Transforming growth factor; TNF-α: Tumor necrosis factor-alpha.
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